Skip to main content
. 2021 Jan 20;100(5):1303–1309. doi: 10.1007/s00277-021-04413-2

Fig. 1.

Fig. 1

a The 3-year DFS was 60.8% in the UCBT group and 10% in the chemotherapy group, and the 3-year DFS in the UCBT group was significantly higher than that in the chemotherapy group (P = 0.003). b The relapse rate was 23.6% in the UCBT group and 85.4% in the chemotherapy group, and the relapse rate in the UCBT group was significantly lower than that in the chemotherapy group (P < 0.001). c The 3-year GRFs was 50% in the UCBT group